Abstract Number: 873 • 2013 ACR/ARHP Annual Meeting
Health Fair Evaluations To Identify Subjects At-Risk For Future Inflammatory Arthritis and Rheumatoid Arthritis
Background/Purpose: Multiple studies demonstrate that there is a preclinical period of rheumatoid arthritis (RA) when autoantibodies (Abs) including RF and anti-CCP are abnormal in absence…Abstract Number: 874 • 2013 ACR/ARHP Annual Meeting
Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Background/Purpose: To report on sustainability and consistency of ACR component scores with intravenous (IV) golimumab (GLM) 2mg/kg+methotrexate (MTX) through wk52 in pts with active rheumatoid…Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting
Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting
Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Background/Purpose: Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell…Abstract Number: 877 • 2013 ACR/ARHP Annual Meeting
Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis
Background/Purpose: The FDA-approved dose of rituximab (RTX) in rheumatoid arthritis (RA) is 2 × 1000 mg IV infusions given 2 weeks apart (1 course), with…Abstract Number: 878 • 2013 ACR/ARHP Annual Meeting
Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis
Background/Purpose: As biological treatments for rheumatoid arthritis (RA) are only effective in a subpopulation of patients and the treatment can have serious side effects, there…Abstract Number: 879 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized debilitating joint destruction, if not treated aggressively in the patient in most need of treatment. …Abstract Number: 880 • 2013 ACR/ARHP Annual Meeting
Role Of Urinary Podocyte Number and Urinary Podocalyxin Level As Biomarkers Of Glomerulonephritis In Systemic Lupus Erythematosus and ANCA-Associated Vasculitis
Background/Purpose: Podocytes are glomerular visceral epithelial cells functioning as molecular sieves not to allow high molecular weight protein to leak from glomerular capillary wall. The…Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting
Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes
Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…Abstract Number: 883 • 2013 ACR/ARHP Annual Meeting
Sex Bias In Autoimmune Diseases: Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SS) Supports The Gene Dose Hypothesis
Background/Purpose: Female preponderance is a hallmark of most autoimmune diseases, the mechanism for which is unknown. We hypothesize that this is a consequence of a…Abstract Number: 884 • 2013 ACR/ARHP Annual Meeting
Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial
Background/Purpose: Studies in murine models for SLE have shown that CTLA4Ig can ameliorate murine lupus nephritis. Moreover, the combination of CTLA4Ig plus intravenous cyclophosphamide (IVC)…Abstract Number: 885 • 2013 ACR/ARHP Annual Meeting
Fatigue In SLE Is Associated With Upregulation Of Interferon- Alpha Related Gene Transcripts
Background/Purpose: Fatigue is a major complaint in at least 80% of SLE patients, and is often listed as the most disabling symptom of the disease;…Abstract Number: 886 • 2013 ACR/ARHP Annual Meeting
Lupus Neutrophil Extracellular Traps Render High Density Lipoprotein Oxidized and proatherogenic
Background/Purpose: Cardiovascular risk is significantly increased in systemic lupus erythematosus (SLE) patients. This phenomenon cannot be explained by the Framingham risk equation. Previous reports suggest that…Abstract Number: 887 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…
ACR Meeting Abstracts